An Interview With Cheryl Schwartz, Takeda's Senior Vice-President of US Rare Disease Business

Larry Luxner, senior correspondent for Rare Disease Advisor, interviews Cheryl Schwartz, Takeda's senior vice-president of US rare disease business, on the recent approval of lanadelumab-flyo (Takhzyro®) for hereditary angioedema.